WOAH Reference Laboratory Reports Activities 2023
Activities in 2023
This report has been submitted: 29 avril 2024 17:08

TOR1: DIAGNOSTIC METHODS

1. Did your laboratory perform diagnostic tests for the specified disease/topic for purposes such as disease diagnosis, screening of animals for export, surveillance, etc.? (Not for quality control, proficiency testing or staff training)

Yes

<table>
<thead>
<tr>
<th>Diagnostic Test</th>
<th>Indicated in WOAH Manual (Yes/No)</th>
<th>Total number of test performed last year</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Indirect diagnostic tests</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ELISA gB</td>
<td>Yes</td>
<td>817</td>
</tr>
<tr>
<td>ELISA gE</td>
<td>No</td>
<td>479</td>
</tr>
<tr>
<td>Virus neutralisation Test</td>
<td>No</td>
<td>84</td>
</tr>
<tr>
<td><strong>Direct diagnostic tests</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PCR</td>
<td>Yes</td>
<td>180</td>
</tr>
<tr>
<td>Virus Isolation</td>
<td>No</td>
<td>40</td>
</tr>
</tbody>
</table>

TOR2: REFERENCE MATERIAL

2. Did your laboratory produce or supply imported standard reference reagents officially recognised by WOAH?

Yes

<table>
<thead>
<tr>
<th>TYPE OF REAGENT AVAILABLE</th>
<th>RELATED DIAGNOSTIC TESTING</th>
<th>PRODUCED/IMPORTED</th>
<th>QUANTITY SUPPLIED NATIONWIDE (ML, MG)</th>
<th>QUANTITY SUPPLIED AT INTERNATIONAL LEVEL (ML, MG)</th>
<th>NAME OF BENEFICIARY WOAH MEMBER COUNTRIES</th>
</tr>
</thead>
<tbody>
<tr>
<td>Serum sub-standard ADV1 gB</td>
<td>ELISA gB</td>
<td>24 mL</td>
<td>22 mL</td>
<td>2 mL</td>
<td>FRANCE, UNITED KINGDOM,</td>
</tr>
<tr>
<td>Serum sub-standard ADV1 gE</td>
<td>ELISA gE</td>
<td>24 mL</td>
<td>11 mL</td>
<td>13 mL</td>
<td>FRANCE, PORTUGAL, SWITZERLAND, UNITED KINGDOM,</td>
</tr>
<tr>
<td>Positive control sera</td>
<td>ELISA gB &amp; gE</td>
<td>59 mL</td>
<td>4 mL</td>
<td>55 mL</td>
<td>FRANCE, SWITZERLAND,</td>
</tr>
<tr>
<td>AD virus inactivated strains</td>
<td>PCR</td>
<td>0.5 mL</td>
<td>0.5 mL</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>International reference serum ADV1</td>
<td>International reference ELISA gB &amp; GE</td>
<td>1</td>
<td>0</td>
<td>1.4 mL</td>
<td>2</td>
</tr>
</tbody>
</table>

3. Did your laboratory supply standard reference reagents (non-WOAH-approved) and/or other diagnostic reagents to WOAH Members?

Yes

<table>
<thead>
<tr>
<th>TYPE OF REAGENT AVAILABLE</th>
<th>RELATED DIAGNOSTIC TEST</th>
<th>PRODUCED/ PROVIDE</th>
<th>AMOUNT SUPPLIED NATIONWIDE (ML, MG)</th>
<th>AMOUNT SUPPLIED INTERNATIONALLY (ML, MG)</th>
<th>NO. OF RECIPIENT WOAH MEMBER COUNTRIES</th>
<th>COUNTRY OF RECIPIENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Serum sub-standard ADV1 gB</td>
<td>ELISA gB</td>
<td>24 mL</td>
<td>22 mL</td>
<td>2 mL</td>
<td>2</td>
<td>FRANCE, UNITED KINGDOM,</td>
</tr>
<tr>
<td>Serum sub-standard ADV1 gE</td>
<td>ELISA gE</td>
<td>24 mL</td>
<td>11 mL</td>
<td>13 mL</td>
<td>4</td>
<td>FRANCE, PORTUGAL, SWITZERLAND, UNITED KINGDOM,</td>
</tr>
<tr>
<td>Positive control sera</td>
<td>ELISA gB &amp; gE</td>
<td>59 mL</td>
<td>4 mL</td>
<td>55 mL</td>
<td>2</td>
<td>FRANCE, SWITZERLAND,</td>
</tr>
<tr>
<td>AD virus inactivated strains</td>
<td>PCR</td>
<td>0.5 mL</td>
<td>0.5 mL</td>
<td>0</td>
<td>1</td>
<td>FRANCE,</td>
</tr>
<tr>
<td>International reference serum ADV1</td>
<td>International reference ELISA gB &amp; GE</td>
<td>1</td>
<td>0</td>
<td>1.4 mL</td>
<td>2</td>
<td>FRANCE, PORTUGAL,</td>
</tr>
</tbody>
</table>

4. Did your laboratory produce vaccines?

No

5. Did your laboratory supply vaccines to WOAH Members?

No

TOR3: NEW PROCEDURES

6. Did your laboratory develop new diagnostic methods for the designated pathogen or disease?

WOAH Reference Laboratory Reports Activities 2023
No

7. Did your laboratory validate diagnostic methods according to WOAH Standards for the designated pathogen or disease?
   No

8. Did your laboratory develop new vaccines for the designated pathogen or disease?
   No

9. Did your laboratory validate vaccines according to WOAH Standards for the designated pathogen or disease?
   No

**TOR4: DIAGNOSTIC TESTING FACILITIES**

10. Did your laboratory carry out diagnostic testing for other WOAH Members?
    No

11. Did your laboratory provide expert advice in technical consultancies on the request of an WOAH Member?
    Yes

<table>
<thead>
<tr>
<th>NAME OF THE WOAH MEMBER COUNTRY RECEIVING A TECHNICAL CONSULTANCY</th>
<th>PURPOSE</th>
<th>HOW THE ADVICE WAS PROVIDED</th>
</tr>
</thead>
<tbody>
<tr>
<td>SWEDEN</td>
<td>request for an opinion on the evaluation of performance of a commercial ELISA kit for the detection of antibodies</td>
<td>e-mail</td>
</tr>
</tbody>
</table>

**TOR5: COLLABORATIVE SCIENTIFIC AND TECHNICAL STUDIES**

12. Did your laboratory participate in international scientific studies in collaboration with WOAH Members other than the own?
    No

13. In exercising your activities, have you identified any regulatory research needs\* relevant for WOAH?
    No

**TOR6: EPIZOOLOGICAL DATA**

14. Did your Laboratory collect epidemiological data relevant to international disease control?
    No

15. Did your laboratory disseminate epidemiological data that had been processed and analysed?
    Yes

<table>
<thead>
<tr>
<th>IF THE ANSWER IS YES, PLEASE PROVIDE DETAILS OF THE DATA COLLECTED:</th>
</tr>
</thead>
<tbody>
<tr>
<td>The data are collected at national level by active and passive surveillance in domestic pigs, wild boars and other susceptible animals (dogs, cats, cattle)</td>
</tr>
</tbody>
</table>

16. What method of dissemination of information is most often used by your laboratory? (Indicate in the appropriate box the number by category and list the details in the box)

   a) Articles published in peer-reviewed journals:

   1


   b) International conferences:

   0

   c) National conferences:

   0
d) Other (Provide website address or link to appropriate information):

Plateforme de Surveillance Santé Animale : https://www.plateforme-esa.fr/fr

**TOR7: SCIENTIFIC AND TECHNICAL TRAINING**

17. Did your laboratory provide scientific and technical training to laboratory personnel from other WOAH Members?
No

**TOR8: QUALITY ASSURANCE**

18. Does your laboratory have a Quality Management System?
Yes

<table>
<thead>
<tr>
<th>Test for which your laboratory is accredited</th>
<th>Accreditation body</th>
</tr>
</thead>
<tbody>
<tr>
<td>ELISA gB</td>
<td>COFRAC : Comité français d'accréditation</td>
</tr>
<tr>
<td>ELISA gE</td>
<td>COFRAC</td>
</tr>
<tr>
<td>PCR</td>
<td>COFRAC</td>
</tr>
<tr>
<td>VIRUS ISOLATION</td>
<td>COFRAC</td>
</tr>
</tbody>
</table>

19. Is your quality management system accredited?
Yes

20. Does your laboratory maintain a “biorisk management system” for the pathogen and the disease concerned?
No

**TOR9: SCIENTIFIC MEETINGS**

21. Did your laboratory organise scientific meetings related to the pathogen in question on behalf of WOAH?
No

22. Did your laboratory participate in scientific meetings related to the pathogen in question on behalf of WOAH?
No

**TOR10: NETWORK WITH WOAH REFERENCE LABORATORIES**

23. Did your laboratory exchange information with other WOAH Reference Laboratories designated for the same pathogen or disease?
Not applicable (only WOAH Reference Laboratory designated for the disease)

24. Do you network (collaborate or share information) with other WOAH Reference Laboratories designated for the same pathogen?
Not applicable (Only WOAH Reference Laboratory designated for the disease)

25. Did you organise or participate in inter-laboratory proficiency tests with WOAH Reference Laboratories designated for the same pathogen?
Not applicable (Only WOAH Reference Laboratory designated for the disease)

26. Did your laboratory collaborate with other WOAH Reference Laboratories for the same disease on scientific research projects for the diagnosis or control of the pathogen of interest?
Not applicable (Only WOAH Reference Laboratory designated for the disease)

**TOR11: OTHER INTERLABORATORY PROFICIENCY TESTING**

27. Did your laboratory organise or participate in inter-laboratory proficiency tests with laboratories other than WOAH Reference Laboratories for the same pathogen?
Yes
The Inter-Laboratory Comparison Test (ILCT) was organized to assess the laboratories ability to perform the Aujeszky's Disease serology (ELISA gB and/or ELISA gE)

**ORGANIZER**

26

ELISA gB & ELISA gE

ARGENTINA, AUSTRIA, BELGIUM, COLOMBIA, CROATIA, CZECH REPUBLIC, DENMARK, FINLAND, FRANCE, GERMANY, IRELAND, ITALY, LATVIA, LITHUANIA, POLAND, SERBIA, SLOVAKIA, SPAIN, SWITZERLAND, THE NETHERLANDS, UNITED KINGDOM,

**TOR12: EXPERT CONSULTANTS**

28. Did your laboratory place expert consultants at the disposal of WOAH?

No

29. Additional comments regarding your report:

Yes

The prevalence of Aujeszky's disease (AD) is highly variable depending on the regions. In Europe, most of the countries have achieved a free status regarding this disease or have implemented control or eradication plans. In Europe in general, ELISA and PCR methods are well established in routine use in national reference laboratories, and they do not require confirmatory or differentiation tests from the WOAH reference laboratory. Moreover, we have not received any requests for diagnosis from non-European countries in 2023 as previous years.

However, our laboratory has worked for several years to help any national reference laboratory or kit producer in the world to improve their diagnostic methods by providing reference reagents: international standard or derived control sera and by organising ILCT.

We have not been asked by WOAH to participate to any meeting regarding the AD.

We have not receive any demand for training in 2023.